Institution identification

PURI

https://redirect.ema.europa.eu/resource/16352

Institution ID

16352

Institution full name and acronym

Observational & Pragmatic Research Institute Pte (OPRI)

Institution countries

United Kingdom

Type of institution

Educational Institution
Laboratory/Research/Testing facility

Institution website

ENCePP partner

Yes
Institution description
OPRI aims to improve outcomes for patients by undertaking the highest quality observational and pragmatic clinical research in disease burden and management. We achieve this through direct involvement in the following initiatives:• Initiating,conducting and disseminating original observational database studies that identify and address areas for improvement in patient care,treatments and medical interventions• Initiating,conducting and disseminating original pragmatic clinical research in respiratory medicine.• Working with industry partners to carry out unbiased real life research in the areas of drug development and regulatory compliance• Ensuring effective medical communications of real life research outcomes• Collaborating with clinical,academic and industry partners to drive a vision for inclusion of real life research into all aspects of medical research
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
Yes

Contact

Studies conducted by the institution

A pragmatic, cluster randomized trial evaluating the impact of an enhanced adherence package (dual bronchodilator+add-on+app) on time to treatment failure and other clinical outcomes in exacerbating COPD patients with poor adherence to mono or dual therapy over one year (MAGNIFY)
ADDITION OF ANTIBIOTICS TO USUAL CARE MANAGEMENT OF ASTHMA EXACERBATIONS: A REALLIFE COMPARATIVE EFFECTIVENESS STUDY
An observational cohort study to describe intermittent OCS utilisation and its association with adverse outcomes and healthcare resource use and costs in asthma using the OPCRD and CPRD databases. (The burden of intermittent OCS use in asthma)
An observational evaluation of prescribing of fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist (ICS/LABA): fluticasone propionate / formoterol (FP/FOR) and adverse events in routine primary care at 18-months and 36-months post launch
An observational evaluation of the off-label prescribing and safety of glycopyrronium bromide for symptomatic treatment of severe sialorrhoea (drooling) and/or hyperhidrosis (excessive sweating) (Glycopyrronium Bromide)
An observational historical cohort study to evaluate chronic disease onset associated with long-term oral corticosteroid and it’s cost impact on patients in the OPCRD / CPRD databases
Asthma and Type 2 Comorbidities - Real-life Characterisation of Patients with Active Asthma and Type 2 Asthma Comorbidities
Asthma management in France and the United Kingdom
Benefits of high dose ICS in patients with asthma and high blood eosinophil counts
Biologic Usage Patterns, Clinical Outcomes and Healthcare Resource Utilization (CLEAR)
Burden and consequences of the use of COPD-related systemic corticosteroids (OCS COPD study)
Burden of disease in patients with COPD and high blood eosinophil counts (High eosinophils and COPD)
Burden of severe uncontrolled eosinophilic asthma in the UK population
Cardiopulmonary risk model for patients with chronic obstructive pulmonary disease
Characterising Patient Pathways to the Diagnosis of Idiopathic Pulmonary Fibrosis: Real World Data Study
Characterising patients and examining real-life outcomes for UK patients with COPD initiating on or changing to Fostair (REACH II)
Characteristics of asthma patients at risk of failed Diskus use in primary care: a retrospective cohort study
Characteristics of type 2 asthma phenotypes and oral corticosteroid (OCS) use in the International Severe Asthma Registry (ISAR) (STAR)
Closing the loop for Fabry disease and Pompe disease in the UK (RARE)
COMPARABILITY OF POPULATION DEFINITIONS WITHIN & BETWEEN GLOBAL DATABASES – DEVELOPING TOOLS FOR OBSERVATIONAL RESEARCH (ACO Population Definitions)
COMPARATIVE EFFECTIVENESS AND SAFETY OF BUDESONIDE STERINEBS® VS. PULMICORT RESPULES® IN A US POPULATION OF ASTHMA PATIENTS.
Comparative effectiveness and safety of Salbutamol Sterinebs® vs Ventolin Nebules® in COPD patients.
Comparative Effectiveness of Extra-Fine Particle Inhaled Corticosteroid (ICS) and Alternative Guideline-Recommended Step-Up Options in Pre-School Children
Comparative safety of extrafine beclometasone fixed dose combinations (FDC) and fluticasone FDC in COPD
CRITIKAL Study
Decline In lung-function Among Patients with chronic obstructive Lung disease On maintenance therapy (DIAPLO)
Does the cost of inhaler devices affect therapy adherence and disease outcomes?
Dose response curves for patients prescribed small & large particle ICS formulation: an observational evaluation of the comparative effect of ICS dose on asthma control achieved in real-life UK patients managed on extrafine hydrofluoroalkane beclomethasone, ciclesonide, fluticasone propionate, or Clenil
EffectIveness of bioloGics (by classes) in patieNts with dIfferent combination of T2 biomarkErs (IGNITE)
Effectiveness of Dymista® in patients with allergic rhinitis and asthma
Effectiveness of Fostair® (ICS/LABA) vs. dual bronchodilation (LABA/LAMA) in COPD (FELICITI)
Effectiveness of prescribing similar vs dissimilar devices for COPD management (phase 2)
Effectiveness of triple therapy vs. dual bronchodilation in COPD (Effectiveness of triple therapy in COPD)
Eosinophilic asthma phenotypes and associated clinical outcomes
Evaluation of the undertreatment and disease outcomes for patients with coexisting Heart Failure and Chronic Obstructive Pulmonary Disease
Exacerbation history in COPD patients prior to diagnosis and subsequent treatment and outcomes
Exploring different composite definitions of responders and non-responders to biologic treatment for severe asthma (FULL BEAM)
Hidden Severe Asthma in Primary Care versus ISAR Cohort
Historical matched-cohort study assessing whether the use of inhaled corticosteroids shortens time to first diagnosis or accelerates the progression of side effects compared to non-ICS therapies in patients with Chronic Obstructive Pulmonary Disease. (ICS use in COPD patients and risk of side effects)
ICARUS: Inhaled Corticosteroid And Real life Unlicensed Spacer use – stage 2 (ICARUS 2)
IDENTIFYING OPPORTUNITIES FOR EARLIER DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS IN ROUTINE CARE IN THE UK: A RETROSPECTIVE CLINICAL COHORT STUDY (OPPORTUNITIES FOR EARLIER IPF DIAGNOSIS)
Impact of biologic initiation on steroid burden and new-onset of potentially OCS-related outcomes in patients with severe asthma (SOLAR)
Impact of Optimum Patient Care’s clinical review service (Impact of OPC)
Incidence of oral thrush in COPD patients prescribed ICS as part of ICS/LABA therapy
Inhaled Corticosteroid and Real Life unlicensed Spacer Use (stage 1) (ICARUS 1)
Investigating the possible role of BLood eosinophil counts in guiding ANti-inflammatory treatment of COPD exAcerbations (BLANCA)
Longitudinal systemic corticosteroid utilization in the UK, 1990-2018
Patient characteristics and treatment pathways in patients with asthma or asthma-COPD overlap treated with Medium-Strength ICS/LABA and switching to High-StrEngth ICS/LABA or Medium-Strength TRImbow (BETRI)
Patient characteristics and treatment pathways in patients with COPD initiated on ICS/LABA/LAMA and LABA/LAMA treatment
Randomised Controlled Trial (RCT) vs Real Life initiative (RCT vs Real Life)
Real life effectiveness and cost impact evaluation of fixed dose combination fluticasone propionate/formoterol (Flutiform®) compared to fluticasone propionate/salmeterol (Seretide®) (eFFectiveness)
Real-life effectiveness evaluation of asthma treatment in Korea
Real-life effectiveness evaluation of budesonide/formoterol (BF) Spiromax for the management of asthma and COPD
Real-life effectiveness evaluation of changing inhaler device for asthma treatment in Korea (Transfform)
Real-world effectiveness of extra-fine Ciclesonide (Alvesco®) versus standard particle inhaled corticosteroid (ICS)
Real-world effectiveness of extra-fine formulations in Denmark
Real-world use of Breztri/Trixeo for the management of COPD in a UK primary care population
Redefining severe asthma to high-risk asthma: Analysis of real-world data to investigate patients who are at high risk of exacerbations, worsening of symptoms, and a loss of asthma control over time.
Severe Asthma Super-Responders Delphi Exercise
Studying the value of fractional exhaled Nitric Oxide and blood eosinophils as biomarkers in predicting which patients will suffer from more frequent asthma exacerbations, and evaluating the subsequent healthcare resource utilisation (Assessing RIsk of exAcerbation (ARIA))
The burden of rhinitis in Australia
The role of adherence to inhaled corticosteroids in the relationship between blood eosinophilia and asthma control
The UK nationwide cardiorespiratory impact of the COVID-19 pandemic
The use of a spacer in the delivery of large (Fluticasone Propionate) and small particle (Qvar®) inhaled corticosteroid (ICS) in asthma (FP and Qvar Spacer vs Non-Spacer in Asthma)
Training requirements to master inhaler devices available in real-life clinical practice (TMID)
Twenty years of COPD primary care: Patterns of management of high-risk COPD and opportunities for optimising care in the United Kingdom 2000-2019: Study Protocol (CONQUEST UK Opportunity Analysis)
Understanding high-risk COPD: Analysis of real-world data to investigate characteristics and outcomes in patients with high-risk COPD. (OPRI 2306: High Risk COPD)
Underuse of beta-blockers in patients with heart failure and COPD
Use of degarelix among patients with prostate cancer in daily practice